Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Supratek Pharma Inc.
DescriptionCombination of daunorubicin and two proprietary non-ionic block copolymers
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationLymphoma
Indication DetailsTreat refractory lymphoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today